0
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.102.98. Please contact the publisher to request reinstatement.
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

JAMA Clinical Challenge | 
Elizabeth Juhas , MD; Joseph C. English III, MD
JAMA. 2013;309(4):392-393. doi:10.1001/jama.2012.211717.

From the Food and Drug Administration | 
Jane E. Henney, MD
JAMA. 2000;283(9):1131. doi:10.1001/jama.283.9.1131.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Brief Report  | 
Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma
M. Estela Martinez-Escala, MD; Timothy M. Kuzel, MD; Jason B. Kaplan, MD; et al.
JAMA Oncology
Invited Commentary  | 
Romidepsin Therapy Over 5 Years in a Clinical Setting—Real-World Experience
Susan E. Bates, MD; Larisa J. Geskin, MD
JAMA Dermatology
Observation  | 
Cutaneous T-Cell Lymphoma Misdiagnosed as Lipodermatosclerosis
W. James Tidwell, MD; Janine Malone, MD; Jeffrey P. Callen, MD
JAMA Dermatology
Research Letter  | 
Efficacy and Safety of APO866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma A Phase 2 Clinical Trial
Simone M. Goldinger, MD; Sharon Gobbi Bischof, MD; Regina Fink-Puches, MD; et al.